Although their impact on AML progression and OS is less pronounced [48], ZRSR2 mutations, as well as other splicing factors, are classified among MDS-related gene mutations by both the International Consensus Classification (ICC) and the WHO classification of AML [7,8]. This evidence concerns the gene ZRSR2 and acute myeloid leukemia.